WuXi AppTec Co Ltd (603259) - Net Assets

Latest as of June 2025: CN¥60.41 Billion CNY ≈ $8.84 Billion USD

Based on the latest financial reports, WuXi AppTec Co Ltd (603259) has net assets worth CN¥60.41 Billion CNY (≈ $8.84 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥83.82 Billion ≈ $12.27 Billion USD) and total liabilities (CN¥23.41 Billion ≈ $3.43 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check WuXi AppTec Co Ltd (603259) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥60.41 Billion
% of Total Assets 72.07%
Annual Growth Rate 28.26%
5-Year Change 80.59%
10-Year Change 818.89%
Growth Volatility 51.24

WuXi AppTec Co Ltd - Net Assets Trend (2014–2024)

This chart illustrates how WuXi AppTec Co Ltd's net assets have evolved over time, based on quarterly financial data. See WuXi AppTec Co Ltd (603259) defensive interval to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for WuXi AppTec Co Ltd (2014–2024)

The table below shows the annual net assets of WuXi AppTec Co Ltd from 2014 to 2024. For live valuation and market cap data, see 603259 market cap overview.

Year Net Assets Change
2024-12-31 CN¥59.09 Billion
≈ $8.65 Billion
+6.43%
2023-12-31 CN¥55.52 Billion
≈ $8.12 Billion
+18.31%
2022-12-31 CN¥46.93 Billion
≈ $6.87 Billion
+21.08%
2021-12-31 CN¥38.76 Billion
≈ $5.67 Billion
+18.46%
2020-12-31 CN¥32.72 Billion
≈ $4.79 Billion
+87.93%
2019-12-31 CN¥17.41 Billion
≈ $2.55 Billion
-4.16%
2018-12-31 CN¥18.17 Billion
≈ $2.66 Billion
+169.59%
2017-12-31 CN¥6.74 Billion
≈ $985.98 Million
+11.14%
2016-12-31 CN¥6.06 Billion
≈ $887.12 Million
-5.72%
2015-12-31 CN¥6.43 Billion
≈ $940.93 Million
+31.16%
2014-12-31 CN¥4.90 Billion
≈ $717.42 Million
--

Equity Component Analysis

This analysis shows how different components contribute to WuXi AppTec Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1987.3% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥32.01 Billion 54.59%
Common Stock CN¥2.89 Billion 4.93%
Other Components CN¥23.74 Billion 40.48%
Total Equity CN¥58.63 Billion 100.00%

WuXi AppTec Co Ltd Competitors by Market Cap

The table below lists competitors of WuXi AppTec Co Ltd ranked by their market capitalization.

Company Market Cap
WEC Energy Group Inc
NYSE:WEC
$35.85 Billion
China Hongqiao Group Ltd
F:H0Q
$35.88 Billion
Naspers Limited
JSE:NPN
$35.95 Billion
Keysight Technologies Inc
NYSE:KEYS
$35.96 Billion
Nucor Corp
NYSE:NUE
$35.76 Billion
PG&E Corp
NYSE:PCG
$35.39 Billion
UltraTech Cement Limited
NSE:ULTRACEMCO
$35.31 Billion
Asia Vital Components Co Ltd
TW:3017
$35.28 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in WuXi AppTec Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 55,122,453,910 to 58,632,715,000, a change of 3,510,261,090 (6.4%).
  • Net income of 9,450,308,000 contributed positively to equity growth.
  • Dividend payments of 3,084,877,000 reduced retained earnings.
  • Share repurchases of 3,908,910,000 reduced equity.
  • Other factors increased equity by 1,053,740,090.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥9.45 Billion +16.12%
Dividends Paid CN¥3.08 Billion -5.26%
Share Repurchases CN¥3.91 Billion -6.67%
Other Changes CN¥1.05 Billion +1.8%
Total Change CN¥- 6.37%

Book Value vs Market Value Analysis

This analysis compares WuXi AppTec Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.89x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 80.83x to 4.89x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2014-12-31 CN¥1.22 CN¥98.85 x
2015-12-31 CN¥1.60 CN¥98.85 x
2016-12-31 CN¥2.62 CN¥98.85 x
2017-12-31 CN¥2.86 CN¥98.85 x
2018-12-31 CN¥7.36 CN¥98.85 x
2019-12-31 CN¥6.22 CN¥98.85 x
2020-12-31 CN¥11.43 CN¥98.85 x
2021-12-31 CN¥13.06 CN¥98.85 x
2022-12-31 CN¥14.91 CN¥98.85 x
2023-12-31 CN¥18.59 CN¥98.85 x
2024-12-31 CN¥20.23 CN¥98.85 x

Capital Efficiency Dashboard

This dashboard shows how efficiently WuXi AppTec Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 16.12%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 24.92%
  • • Asset Turnover: 0.47x
  • • Equity Multiplier: 1.37x
  • Recent ROE (16.12%) is above the historical average (14.84%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2014 17.73% 11.15% 0.55x 2.91x CN¥201.22 Million
2015 10.36% 7.15% 0.50x 2.88x CN¥12.20 Million
2016 17.51% 15.94% 0.58x 1.90x CN¥418.06 Million
2017 19.35% 15.80% 0.62x 1.98x CN¥592.86 Million
2018 12.78% 23.51% 0.42x 1.28x CN¥491.72 Million
2019 10.71% 14.41% 0.44x 1.69x CN¥123.33 Million
2020 9.11% 17.90% 0.36x 1.42x CN¥-289.14 Million
2021 13.24% 22.26% 0.42x 1.43x CN¥1.25 Billion
2022 18.92% 22.40% 0.61x 1.39x CN¥4.15 Billion
2023 17.43% 24.84% 0.53x 1.34x CN¥4.09 Billion
2024 16.12% 24.92% 0.47x 1.37x CN¥3.59 Billion

Industry Comparison

This section compares WuXi AppTec Co Ltd's net assets metrics with peer companies in the Diagnostics & Research industry.

Industry Context

  • Industry: Diagnostics & Research
  • Average net assets among peers: $4,802,993,607
  • Average return on equity (ROE) among peers: 14.56%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
WuXi AppTec Co Ltd (603259) CN¥60.41 Billion 17.73% 0.39x $35.78 Billion
Berry Genomics Co Ltd (000710) $130.03 Million 5.29% 2.43x $442.30 Million
Zhejiang DiAn Diagnostics Co (300244) $7.48 Billion 15.56% 1.09x $1.57 Billion
Hangzhou Tigermed Consulting (300347) $17.86 Billion 9.80% 0.09x $4.25 Billion
Beijing Strong Biotechnologies Inc (300406) $987.03 Million 21.34% 0.06x $1.01 Billion
Ningbo MedicalSystem Biotechnology Co Ltd (300439) $202.58 Million 45.28% 0.64x $506.70 Million
Maccura Biotechnology Co Ltd (300463) $6.53 Billion 10.85% 0.25x $817.57 Million
Guangdong Hybribio Biotech Co Ltd (300639) $3.66 Billion -3.58% 0.13x $524.10 Million
BGI Genomics Co Ltd (300676) $9.44 Billion 15.48% 0.51x $2.17 Billion
Amoy Diagnostics Co Ltd (300685) $1.13 Billion 15.98% 0.15x $1.17 Billion
Shanghai Labway Clinical Laboratory Co Ltd (301060) $614.70 Million 9.56% 0.54x $529.82 Million

About WuXi AppTec Co Ltd

SHG:603259 China Diagnostics & Research
Market Cap
$35.78 Billion
CN¥244.48 Billion CNY
Market Cap Rank
#761 Global
#50 in China
Share Price
CN¥98.85
Change (1 day)
-0.90%
52-Week Range
CN¥64.00 - CN¥112.85
All Time High
CN¥165.00
About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more